Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate [4]

Annals of Oncology

Volumn 15, Issue 2, 2004, Pages 358-359

  Arora, B ^a   Kumar, L ^a   Sharma, A ^a   Wadhwa, J ^a   Kochupillai, V ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ARTHRALGIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEPIGMENTATION; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERPIGMENTATION; LETTER; MAJOR CLINICAL STUDY; MELANOGENESIS; MUSCLE CRAMP; MYALGIA; NAUSEA; PIGMENT DISORDER; PRIORITY JOURNAL; SKIN EDEMA; SKIN PIGMENTATION;

ANTINEOPLASTIC AGENTS; EXANTHEMA; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIGMENTATION DISORDERS; PIPERAZINES; PYRIMIDINES;

EID: 1342267582     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh068     Document Type: Letter

References (6)

1. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Valeyrie L, Bastuji-Garin S, Revuz J et al. Adverse cutaneous reactions to Imatinib (STI-571) in Philadelphia chromosome positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-206.
3. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and grey hair. N Engl J Med 2000; 347: 446.
4. Lammie A, Dronjak M, Gerald W et al. Expression of c-kit and kit ligands proteins in normal human tissues. J Histochem Cytochem 1994; 42: 1417-1425.
5. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1999; 113: 139-140.
6. Wu M, Hemesath TJ, Takemoto CM. C-kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000; 14: 301-312.